<- Go Home
Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Market Cap
SEK 107.9M
Volume
1.1M
Cash and Equivalents
SEK 33.9M
EBITDA
-SEK 71.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
SEK 5.23
52 Week Low
SEK 0.70
Dividend
N/A
Price / Book Value
1.24
Price / Earnings
-1.38
Price / Tangible Book Value
3.97
Enterprise Value
SEK 74.7M
Enterprise Value / EBITDA
-1.07
Operating Income
-SEK 71.0M
Return on Equity
100.75%
Return on Assets
-40.35
Cash and Short Term Investments
SEK 33.9M
Debt
SEK 689.0K
Equity
SEK 82.9M
Revenue
N/A
Unlevered FCF
-SEK 62.8M
Sector
Biotechnology
Category
N/A